Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2

Hua Guo, Thomas V. Tittle, Hamish Allen, Richard Maziarz

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Brefeldin A (BFA) has recently been shown to induce apoptosis in human tumor cells in a p53-independent fashion. In this study, BFA-induced apoptosis was analyzed in the human Jurkat T-cell line. Apoptosis occurred 8 h after treatment with BFA and at concentrations as low as 10 ng/ml and increased with the duration of BFA exposure. Forskolin, an inhibitor of BFA- induced deaggregation of the Golgi-microtubular complex in some cell lines, failed to reverse BFA-mediated apoptosis. Further study of the mechanism of BFA-induced apoptosis was conducted by using a series of peptide protease inhibitors. Complete inhibition of cell death was achieved with benzyloxycarbonyl-Val-Ala-Asp-fluromethylketone, a peptide inhibitor of the caspase protease family, and Z-Asp-Glu-Val-Asp-FMK, a specific inhibitor of caspase-3. Both Acetyl-Tyr-Val-Ala-Asp-chloromethylketone and Acetyl-Tyr- Val-Ala-Asp-aldehyde, selective caspase-1 (interleukin-1β converting enzyme) inhibitors, exerted only partial protection of cells from apoptosis at higher concentrations. Z-Phe-Ala-FMK, a cysteine protease inhibitor lacking aspartate at the P1 position, did not have any impact on BFA-induced apoptosis. Furthermore, Jurkat cells transfected with the proto-oncoprotein Bcl-2, which is able to block various apoptotic conditions, showed remarkable resistance to the apoptotic effect of BFA. Thus, the data indicate that BFA- induced apoptosis requires caspase(s) activation, primarily the activation of caspase-3, and is inhibited by overexpression of Bcl-2.

Original languageEnglish (US)
Pages (from-to)57-68
Number of pages12
JournalExperimental Cell Research
Volume245
Issue number1
DOIs
StatePublished - Nov 25 1998

Fingerprint

Brefeldin A
Caspases
Apoptosis
Caspase 1
Jurkat Cells
Protease Inhibitors
Caspase 3
Cysteine Proteinase Inhibitors
Cell Line
Peptides
Caspase Inhibitors
Cytoprotection
Oncogene Proteins
Golgi Apparatus
Enzyme Inhibitors
Colforsin
Aspartic Acid
Cell Death
T-Lymphocytes

ASJC Scopus subject areas

  • Cell Biology

Cite this

Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2. / Guo, Hua; Tittle, Thomas V.; Allen, Hamish; Maziarz, Richard.

In: Experimental Cell Research, Vol. 245, No. 1, 25.11.1998, p. 57-68.

Research output: Contribution to journalArticle

@article{dc29304527454df3a9579dd9925d0d57,
title = "Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2",
abstract = "Brefeldin A (BFA) has recently been shown to induce apoptosis in human tumor cells in a p53-independent fashion. In this study, BFA-induced apoptosis was analyzed in the human Jurkat T-cell line. Apoptosis occurred 8 h after treatment with BFA and at concentrations as low as 10 ng/ml and increased with the duration of BFA exposure. Forskolin, an inhibitor of BFA- induced deaggregation of the Golgi-microtubular complex in some cell lines, failed to reverse BFA-mediated apoptosis. Further study of the mechanism of BFA-induced apoptosis was conducted by using a series of peptide protease inhibitors. Complete inhibition of cell death was achieved with benzyloxycarbonyl-Val-Ala-Asp-fluromethylketone, a peptide inhibitor of the caspase protease family, and Z-Asp-Glu-Val-Asp-FMK, a specific inhibitor of caspase-3. Both Acetyl-Tyr-Val-Ala-Asp-chloromethylketone and Acetyl-Tyr- Val-Ala-Asp-aldehyde, selective caspase-1 (interleukin-1β converting enzyme) inhibitors, exerted only partial protection of cells from apoptosis at higher concentrations. Z-Phe-Ala-FMK, a cysteine protease inhibitor lacking aspartate at the P1 position, did not have any impact on BFA-induced apoptosis. Furthermore, Jurkat cells transfected with the proto-oncoprotein Bcl-2, which is able to block various apoptotic conditions, showed remarkable resistance to the apoptotic effect of BFA. Thus, the data indicate that BFA- induced apoptosis requires caspase(s) activation, primarily the activation of caspase-3, and is inhibited by overexpression of Bcl-2.",
author = "Hua Guo and Tittle, {Thomas V.} and Hamish Allen and Richard Maziarz",
year = "1998",
month = "11",
day = "25",
doi = "10.1006/excr.1998.4235",
language = "English (US)",
volume = "245",
pages = "57--68",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2

AU - Guo, Hua

AU - Tittle, Thomas V.

AU - Allen, Hamish

AU - Maziarz, Richard

PY - 1998/11/25

Y1 - 1998/11/25

N2 - Brefeldin A (BFA) has recently been shown to induce apoptosis in human tumor cells in a p53-independent fashion. In this study, BFA-induced apoptosis was analyzed in the human Jurkat T-cell line. Apoptosis occurred 8 h after treatment with BFA and at concentrations as low as 10 ng/ml and increased with the duration of BFA exposure. Forskolin, an inhibitor of BFA- induced deaggregation of the Golgi-microtubular complex in some cell lines, failed to reverse BFA-mediated apoptosis. Further study of the mechanism of BFA-induced apoptosis was conducted by using a series of peptide protease inhibitors. Complete inhibition of cell death was achieved with benzyloxycarbonyl-Val-Ala-Asp-fluromethylketone, a peptide inhibitor of the caspase protease family, and Z-Asp-Glu-Val-Asp-FMK, a specific inhibitor of caspase-3. Both Acetyl-Tyr-Val-Ala-Asp-chloromethylketone and Acetyl-Tyr- Val-Ala-Asp-aldehyde, selective caspase-1 (interleukin-1β converting enzyme) inhibitors, exerted only partial protection of cells from apoptosis at higher concentrations. Z-Phe-Ala-FMK, a cysteine protease inhibitor lacking aspartate at the P1 position, did not have any impact on BFA-induced apoptosis. Furthermore, Jurkat cells transfected with the proto-oncoprotein Bcl-2, which is able to block various apoptotic conditions, showed remarkable resistance to the apoptotic effect of BFA. Thus, the data indicate that BFA- induced apoptosis requires caspase(s) activation, primarily the activation of caspase-3, and is inhibited by overexpression of Bcl-2.

AB - Brefeldin A (BFA) has recently been shown to induce apoptosis in human tumor cells in a p53-independent fashion. In this study, BFA-induced apoptosis was analyzed in the human Jurkat T-cell line. Apoptosis occurred 8 h after treatment with BFA and at concentrations as low as 10 ng/ml and increased with the duration of BFA exposure. Forskolin, an inhibitor of BFA- induced deaggregation of the Golgi-microtubular complex in some cell lines, failed to reverse BFA-mediated apoptosis. Further study of the mechanism of BFA-induced apoptosis was conducted by using a series of peptide protease inhibitors. Complete inhibition of cell death was achieved with benzyloxycarbonyl-Val-Ala-Asp-fluromethylketone, a peptide inhibitor of the caspase protease family, and Z-Asp-Glu-Val-Asp-FMK, a specific inhibitor of caspase-3. Both Acetyl-Tyr-Val-Ala-Asp-chloromethylketone and Acetyl-Tyr- Val-Ala-Asp-aldehyde, selective caspase-1 (interleukin-1β converting enzyme) inhibitors, exerted only partial protection of cells from apoptosis at higher concentrations. Z-Phe-Ala-FMK, a cysteine protease inhibitor lacking aspartate at the P1 position, did not have any impact on BFA-induced apoptosis. Furthermore, Jurkat cells transfected with the proto-oncoprotein Bcl-2, which is able to block various apoptotic conditions, showed remarkable resistance to the apoptotic effect of BFA. Thus, the data indicate that BFA- induced apoptosis requires caspase(s) activation, primarily the activation of caspase-3, and is inhibited by overexpression of Bcl-2.

UR - http://www.scopus.com/inward/record.url?scp=0031740863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031740863&partnerID=8YFLogxK

U2 - 10.1006/excr.1998.4235

DO - 10.1006/excr.1998.4235

M3 - Article

VL - 245

SP - 57

EP - 68

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 1

ER -